ArticleEuropean journal of nuclear medicine and molecular imaging2017
Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with
Article in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03939689 (A Multicenter, Randomized, Controlled Phase 2 Study), which is not on this map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Randomized, Controlled Phase 2 Study: Efficacy and Safety of I-131-1095 Radiotherapy in Combination With Enzalutamide in mCRPC Patients Who Are 18F-DCFPyL PSMA-avid, Chemotherapy-naïve, and Progressed on Abiraterone (ARROW )
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Beyond [BMC cancer · 2026Pooled it
- Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.International journal of molecular sciences · 2022Pooled it
- 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Single Photon Emission Computed Tomography Tracer.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients.Journal of experimental & clinical cancer research : CR · 2024Review
- Alpha Particle-Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery.Molecular imaging and biology · 2023Review
- Comparative Analysis of Morphological and Functional Effects ofInternational journal of molecular sciences · 2023Article
- Development of [European journal of nuclear medicine and molecular imaging · 2023Article
- [New tracers and combinations in radioligand therapy for prostate cancer].Urologie (Heidelberg, Germany) · 2023Review
- Review
- Current status of PSMA-targeted imaging and therapy.Frontiers in oncology · 2023Review
- Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer - a narrative review.Frontiers in oncology · 2023Review
- Current Status of PSMA-Targeted Radioligand Therapy in the Era of Radiopharmaceutical Therapy Acquiring Marketing Authorization.Nuclear medicine and molecular imaging · 2022Review
- Pharmacological Optimization of PSMA-Based Radioligand Therapy.Biomedicines · 2022Review
- Advances in PSMA theranostics.Translational oncology · 2022Article
- Prostate specific membrane antigen binding radiopharmaceuticals: Current data and new concepts.Frontiers in medicine · 2022Review
- Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy.Pharmaceuticals (Basel, Switzerland) · 2021Review
- The effect of eating on the uptake of PSMA ligands in the salivary glands.EJNMMI research · 2021Article
- PSMA Theranostics: Current Landscape and Future Outlook.Cancers · 2021Review
- PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProstate-specific membrane antigen (PSMA)-targeting radioligand therapy (RLT) was introduced in 2011. The first report described the antitumor and side effects of a single dose. The aim of this analysis was to evaluate toxicity and antitumor activity after single and repetitive therapies.
methodsThirty-four men with metastatic castration-resistant prostate cancer received PSMA-RLT with
resultsThe best therapeutic effect was achieved by the first therapy. A PSA decline of ≥50% was achieved in 70.6% of the patients. The second and third therapies were significantly less effective. There was neither an association between the applied activity and PSA response or the time-to-progression. Hematologic toxicities were less prevalent but presented in a higher percentage of patients with increasing number of therapies. After hematologic toxicities, xerostomia was the second most frequent side effect and presented more often and with higher intensity after the second or third therapy.
conclusionThe first dose of RLT with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.